Five-Year Outcomes of Proton Therapy in Localized Prostate Cancer on 3 Prospective Trials for Low-, Intermediate-, and High-Risk Prostate Cancer

被引：1
|
作者：
Mendenhall, N. P. [1 ]
Hoppe, B. S. [1 ]
Morris, C. G. [1 ]
Nichols, R. C. [1 ]
Mendenhall, W. M. [1 ]
Su, Z. [1 ]
Li, Z. [1 ]
Williams, C. R. [2 ]
Costa, J. [2 ]
Henderson, R. H. [1 ]
机构：
[1] Univ Florida, Proton Therapy Inst, Jacksonville, FL USA
[2] Univ Florida, Coll Med, Dept Surg, Div Urol, Jacksonville, FL USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2013年 / 87卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2013.06.400
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 50 条
  • [21] Image-Guided Proton Therapy for Low- and Intermediate-Risk Prostate Cancer: Three-Year Results of Two Prospective Trials
    Henderson, R. H.
    Hoppe, B. S.
    Nichols, R.
    Mendenhall, W. M.
    Marcus, R. B.
    Su, Z.
    Williams, C.
    Morris, C. G.
    Mendenhall, N. P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S396 - S396
  • [22] Outcomes of Hypofractionated SBRT Boost for Intermediate- and High-Risk Prostate Cancer: A Single Institutional Prospective Study
    Anwar, M.
    Weinberg, V.
    Hsu, I. J.
    Roach, M.
    Gottschalk, A. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S105 - S106
  • [23] Thermal Partial Prostate Ablation for Intermediate- and High-risk Prostate Cancer: Con
    Gaffney, Christopher D.
    Ehdaie, Behfar
    EUROPEAN UROLOGY FOCUS, 2023, 9 (04): : 660 - 661
  • [24] Seven-Year Outcomes of a Prospective Trial of Concomitant Docetaxel and Proton Therapy for High-Risk Prostate Cancer
    Mendenhall, N. P.
    Bryant, C. M.
    Hoppe, B. S.
    Nichols, R. C., Jr.
    Mendenhall, W. M.
    Morris, C. G.
    Li, Z.
    Williams, C. R.
    Costa, J. A.
    Henderson, R. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S47 - S47
  • [25] Five-Year Outcomes From a Prospective Trial of Image Guided Accelerated Hypofractionated Proton Therapy for Prostate Cancer
    Henderson, R. H.
    Hoppe, B. S.
    Bryant, C. M.
    Mendenhall, W. M.
    Nichols, R. C., Jr.
    Li, Z.
    Su, Z.
    Morris, C. G.
    Costa, J. A.
    Mendenhall, N. P.
    Williams, C. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : S199 - S199
  • [26] Stereotactic body radiation therapy for low-, intermediate- and high-risk prostate cancer: Disease control and quality of life at 9 years
    Katz, Alan J.
    Kang, Josephine
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [27] Stereotactic Body Radiation Therapy for Low-, Intermediate-, and High-Risk Prostate Cancer: Disease Control and Quality of Life at 6 Years
    Katz, A.
    Kang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2013, 87 (02): : S24 - S25
  • [28] Image-guided proton therapy for low- and intermediate-risk prostate cancer: Three-year results of two prospective trials.
    Henderson, Randal H.
    Hoppe, Bradford S.
    Nichols, Romaine Charles
    Mendenhall, William M.
    Marcus, Robert B.
    Su, Zhong
    Williams, Christopher R.
    Li, Zuofeng
    Morris, Christopher G.
    Mendenhall, Nancy Price
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [29] Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Morgan, Peter B.
    Hanlon, Alexandra L.
    Horwitz, Eric M.
    Buyyounouski, Mark K.
    Uzzo, Robert G.
    Pollack, Alan
    CANCER, 2007, 110 (01) : 68 - 80
  • [30] Value of PHI and PHID in the detection of intermediate- and high-risk prostate cancer
    Filella, Xavier
    Foj, Laura
    Wijngaard, Robin
    Luque, Pilar
    CLINICA CHIMICA ACTA, 2022, 531 : 277 - 282
12345